ViaCyte Substantially Expands Patent Portfolio in Stem Cell-Derived Cell Replacement Therapies for Type 1 Diabetes … – PR Newswire (press release)
|
ViaCyte Substantially Expands Patent Portfolio in Stem Cell-Derived Cell Replacement Therapies for Type 1 Diabetes …
PR Newswire (press release) "ViaCyte's intellectual property covers directed differentiation to various cell types from numerous pluripotent stem cell sources, including embryonic and induced pluripotent stem cells, by multiple methods, as well as delivery and encapsulation … |
